A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania

Xenia Bacinschi; Gabriel Cristian Popescu; Anca Zgura; Laurentia Gales; Anghel Rodica; Adriana Mercan; Dragos Serban; Bogdan Haineala; Letitia Toma; Laura Iliescu

doi:10.12659/MSM.936706

05 July 2022 : Clinical Research

A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania

Xenia Bacinschi^1E, Gabriel Cristian Popescu^2C, Anca Zgura^1C*, Laurentia Gales^3F, Anghel Rodica^1A, Adriana Mercan^4D, Dragos Serban^5D, Bogdan Haineala^6B, Letitia Toma^4C, Laura Iliescu^4F

DOI: 10.12659/MSM.936706

Med Sci Monit 2022; 28:e936706

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Common adverse reactions in the study groups.

	Total group (N=587 patients)	Without ribavirin (n=343 patients)	With ribavirin (n=245 patients)	Chi-square
Asthenia	178 patients (30.32%)	56 patients (16.37%)	112 patients (49.79%)	−0.52
Nausea	213 patients (36.28%)	98 patients (28.57%)	115 patients (46.93%)	−0.47
Headaches	132 patients (22.48%)	43 patients (12.53%)	89 patients (36.32%)	−0.33

Back to the Article

A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania

Your Privacy